F11R Antikörper (Extracellular Domain) (FITC)

Produktnummer ABIN1106269

Dieser Maus Monoklonal Antikörper detektiert spezifisch F11R in WB, FACS, IF und IHC (fro). Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für F11R Antikörper (Extracellular Domain) (FITC) (ABIN1106269)

Target: F11R (F11 Receptor (F11R))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser F11R Antikörper ist konjugiert mit FITC

Applikation: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Frozen Sections) (IHC (fro))

Klon: BV16

Produktdetails anti-F11R Antikörper (FITC)

Bindungsspezifität: Extracellular Domain

Spezifität: The monoclonal antibody BV16 recognizes the human junction adhesion molecule (JAM)-A.

Kreuzreaktivität (Details): Species reactivity (tested):Human

Aufreinigung: Potein G

Immunogen: Fusion protein consisting of the extracellular domain of human JAM and the Fc portion of human IgGs

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.1 mg/mL

Buffer: PBS, 0.02 % sodium azide, 1 % bovine serum albumin

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Prior to reconstitution store at 2-8 °C. Following reconstitution store undiluted at 2-8 °C for one month or or (in aliquots) at -20 °C for longer.

Details zu F11R

Target: F11R (F11 Receptor (F11R))

Andere Bezeichnung: CD321 / JAM1

Hintergrund: Together with JAM-C (JAM-2) and JAM-B (VE-JAM or JAM-3), JAM-A belongs to a family of adhesion proteins with a V-C2 immunoglobulin domain organization and their molecular weight is about 30-40 kDa. JAMs are important for a variety of cellular processes, including tight junction assembly, leukocyte transmigration, platelet activation, angiogenesis and virus binding. JAM-A is expressed by endothelial and epithelial cells, platelets, neutrophils, monocytes, lymphocytes and erythrocytes. Like all other JAMs, JAM-A plays an important role in tight junctions where it is involved in cell-to-cell adhesion through homophilic interaction. It codistributes with other tight junction components as ZO-1, 7H6 antigen, cingulin and occludin. JAM-A also plays an important role in leukocyte transmigration. Leukocyte transmigration can be blocked by antibodies and by soluble JAM-A/Fc fusion proteins. Homophilic JAM-A interactions between leukocytes and the endothelium but also heterophilic interactions of JAM-A with the beta2-integrin leukocyte function-associated antigen-1 (LFA-1) are considered to actively guide leukocytes during transmigration. Several studies imply a role for JAM-A in the initiation of atherosclerosis since JAM-A is upregulated on early atherosclerotic endothelium. The adhesion of activated platelets on the activated endothelium is mediated by homophilic interactions of JAM-A.Synonyms: F11R, JAM-A, JCAM, Junctional adhesion molecule 1, Junctional adhesion molecule A, PAM1, Platelet F11 receptor, Platelet adhesion molecule 1

Gen-ID: 50848

NCBI Accession: NP_058642

UniProt: Q9Y624

Pathways: Cell-Cell Junction Organization